These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30928014)

  • 1. Bridging the Efficacy-Effectiveness Gap in the Antipsychotic Treatment of Schizophrenia: Back to the Basics.
    Ramesh B; Tandon R
    Asian J Psychiatr; 2019 Feb; 40():A1-A2. PubMed ID: 30928014
    [No Abstract]   [Full Text] [Related]  

  • 2. Bridging the efficacy-effectiveness gap in the antipsychotic treatment of schizophrenia: back to the basics.
    Tandon R
    J Clin Psychiatry; 2014 Nov; 75(11):e1321-2. PubMed ID: 25470099
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacogenetics of antipsychotic treatment in schizophrenia.
    Pouget JG; Müller DJ
    Methods Mol Biol; 2014; 1175():557-87. PubMed ID: 25150876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bridging pharmacology and neurodevelopment in schizophrenia.
    Kato T
    Int J Neuropsychopharmacol; 2007 Dec; 10(6):713-6. PubMed ID: 17651523
    [No Abstract]   [Full Text] [Related]  

  • 5. Conventional antipsychotic medications for schizophrenia.
    Dixon LB; Lehman AF; Levine J
    Schizophr Bull; 1995; 21(4):567-77. PubMed ID: 8749885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 7. Improved antisaccade performance in schizophrenia with risperidone.
    Hutton SB
    J Neurol Neurosurg Psychiatry; 2002 Apr; 72(4):429. PubMed ID: 11909895
    [No Abstract]   [Full Text] [Related]  

  • 8. Atypical antipsychotic drugs for schizophrenia.
    Luh JY
    Mayo Clin Proc; 2003 Mar; 78(3):381-2. PubMed ID: 12630594
    [No Abstract]   [Full Text] [Related]  

  • 9. Cognitive effects of conventional and atypical antipsychotics in schizophrenia.
    Sharma T
    Br J Psychiatry Suppl; 1999; (38):44-51. PubMed ID: 10884899
    [No Abstract]   [Full Text] [Related]  

  • 10. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
    Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ;
    Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Antipsychotic Dosing Regimen on Neurocognition in Schizophrenia.
    Takeuchi H; Fervaha G; Remington G
    J Clin Psychopharmacol; 2015 Dec; 35(6):728-30. PubMed ID: 26479222
    [No Abstract]   [Full Text] [Related]  

  • 12. Schizophrenia and the microbiome: Time to focus on the impact of antipsychotic treatment on the gut microbiota.
    Dinan TG; Cryan JF
    World J Biol Psychiatry; 2018 Dec; 19(8):568-570. PubMed ID: 30394174
    [No Abstract]   [Full Text] [Related]  

  • 13. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder.
    Sharma RP; Janicak PG; Bissette G; Nemeroff CB
    Am J Psychiatry; 1997 Jul; 154(7):1019-21. PubMed ID: 9210757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.
    Lieberman JA; Bymaster FP; Meltzer HY; Deutch AY; Duncan GE; Marx CE; Aprille JR; Dwyer DS; Li XM; Mahadik SP; Duman RS; Porter JH; Modica-Napolitano JS; Newton SS; Csernansky JG
    Pharmacol Rev; 2008 Sep; 60(3):358-403. PubMed ID: 18922967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for neuroprotective effects of antipsychotic drugs: implications for the pathophysiology and treatment of schizophrenia.
    Li XM; Xu H
    Int Rev Neurobiol; 2007; 77():107-42. PubMed ID: 17178473
    [No Abstract]   [Full Text] [Related]  

  • 16. Paliperidone (Invega) for schizophrenia.
    Med Lett Drugs Ther; 2007 Mar; 49(1256):21-3. PubMed ID: 17351558
    [No Abstract]   [Full Text] [Related]  

  • 17. Lurasidone in the treatment of schizophrenia: a critical evaluation.
    Bruijnzeel D; Yazdanpanah M; Suryadevara U; Tandon R
    Expert Opin Pharmacother; 2015; 16(10):1559-65. PubMed ID: 26111577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Towards better non-selectivity: the role of 5-HT7 receptors in therapeutic efficacy of a second-generation antipsychotic - lurasidone].
    Bieńkowski P; Dudek D; Samochowiec J
    Psychiatr Pol; 2015; 49(2):243-53. PubMed ID: 26093589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroquel: a putative atypical antipsychotic drug with serotonin- and dopamine-receptor antagonist properties. Preclinical and early clinical trials in schizophrenia.
    J Clin Psychiatry; 1995 Sep; 56(9):438-45. PubMed ID: 7665549
    [No Abstract]   [Full Text] [Related]  

  • 20. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.